Related Experiment Video
Updated: Feb 5, 2026

Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting
Published on: April 9, 2019
Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations
Jasmine A Luzum1, Jason C Cheung1,2
1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Insights
Pharmacogenetic testing for clopidogrel is recommended despite lacking randomized controlled trials, contradicting current guidelines. Evidence supports clopidogrel testing more than other recommended pharmacogenetic tests.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Cardiovascular Medicine
Background:
- Current American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend against routine pharmacogenetic testing for clopidogrel.
- This recommendation contrasts with the Clinical Pharmacogenetics Implementation Consortium and US Food and Drug Administration (FDA) stances.
- The AHA/ACC cites a lack of randomized controlled trials demonstrating improved patient outcomes as the basis for their recommendation.
Purpose of the Study:
- To compare the evidence supporting pharmacogenetic testing for clopidogrel with that of other pharmacogenetic tests recommended by the AHA/ACC and National Comprehensive Cancer Network (NCCN).
- To evaluate the consistency of guideline recommendations regarding pharmacogenetic testing in the absence of randomized controlled trial evidence.
Main Methods:
- A comparative analysis of existing evidence for pharmacogenetic tests recommended by major health organizations.
- Focus on clopidogrel pharmacogenetic testing in patients undergoing percutaneous coronary intervention.
Main Results:
- The evidence supporting pharmacogenetic testing for clopidogrel is more robust than for other pharmacogenetic tests endorsed by the AHA/ACC and NCCN.
- Guideline discrepancies exist regarding the necessity of randomized controlled trials for recommending pharmacogenetic tests.
Conclusions:
- Pharmacogenetic testing for clopidogrel may be warranted despite current guideline limitations.
- There is a need for re-evaluation of guideline recommendations for pharmacogenetic testing based on comprehensive evidence, not solely randomized controlled trials.
Abstract:
Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The AHA/ACC recommends against routine pharmacogenetic testing for clopidogrel because no randomized controlled trials have demonstrated that testing improves patients' outcomes. However the AHA/ACC and the National Comprehensive Cancer Network (NCCN) recommend other pharmacogenetic tests in the absence of randomized controlled trials evidence. Using clopidogrel as a case example, we compared the evidence for other pharmacogenetic tests recommended by the AHA/ACC and NCCN. In patients that received percutaneous coronary intervention, the evidence supporting pharmacogenetic testing for clopidogrel is stronger than other pharmacogenetic tests recommended by the AHA/ACC and NCCN.
Related Concept Videos
The Evidence for Evolution
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Measurement: Standard Units
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Standard Enthalpy of Formation
Standard Electrode Potentials

